A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults With Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
MD Anderson Study Status
The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD), and preliminary recommended phase 2 dose(s) (RP2D) of SC administered blinatumomab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
B Cell Precursor Acute Lymphoblastic Leukemia
For general questions about clinical trials: